Novartis AG is paying $75m upfront to use Sangamo Therapeutics, Inc.'s zinc finger technology platform and develop genomic medicines for autism, a long-time area of interest for the Swiss major, and other neurodevelopmental disorders.
The three-year collaboration will see Novartis get exclusive rights to Sangamo's zinc finger protein transcription factors (ZFP-TFs) targeted to three undisclosed genes which are associated with neurodevelopmental disorders, including autism spectrum disorder and intellectual disability
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?